|Bid||1.65 x 6700|
|Ask||1.67 x 100|
|Day's Range||1.65 - 1.76|
|52 Week Range||0.88 - 2.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OncoSec Medical (NASDAQ:ONCS) just hit clinical trial results out of the park in the melanoma arena, with a Phase 2 combination trial that has H.C. Wainwright analyst Ram Selvaraju looking ahead to better clinical outcomes in patients not responsive to solely anti-PD-1 therapy.
It's a very rewarding trading day for investors in OncoSec Medical Inc (NASDAQ:ONCS) with shares up over 180%, making the stock Wall Street's bull of the day.
OncoSec Medical Incorporated (NASDAQ:ONCS), a biotechnology company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As a smallRead More...
An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.